leishmaniasis

Japan’s Global Health Innovative Technology Fund announced $21 million in product development investments on Wednesday.

More than two-thirds of the awards will help advance six ongoing projects, while the rest fund four new investments: a leishmaniasis drug from Takeda and the Drugs for Neglected Diseases initiative; a malaria therapy from Eisai, the Medicines for Malaria Venture and the University of Dundee; a tuberculosis drug from Daiichi Sankyo RD Novare and the TB Alliance; and a…

The Drugs for Neglected Diseases initiative (DNDi) announced new funding this week from Spain’s la Caixa: a grant of $1.2 million over three years to identify “novel natural products” as potentially effective treatments for leishmaniasis and Chagas disease.

DNDi will share the funding with project coordinator Fundación MEDINA and Institut Pasteur Korea, the joint press release said.

Japan’s nonprofit Global Health Innovative Technology Fund (GHIT Fund) on Monday announced $13 million in drug and diagnostic investments.

Three of the seven awards will support new projects for malaria drug development and tests for schistosomiasis and Buruli ulcers. The remaining four will go toward ongoing projects to develop drugs for leishmaniasis, Chagas and soil-transmitted helminths and a rapid diagnostic for malaria.

GHIT Fund’s portfolio now includes 50 ongoing…

Japan’s Global Health Innovative Technology Fund announced yesterday $30 million in new product development investments.

More than two-thirds of the awards will go toward advancing six ongoing projects and the rest to fund five new investments in malaria, leishmaniasis and mycetoma, according to the press release.

The Drugs for Neglected Diseases initiative (DNDi) and Novartis announced yesterday that they have agreed to jointly develop LXE408, a first-in-class compound discovered by Novartis, with financial support from the Wellcome Trust, as a potential new oral treatment for visceral leishmaniasis.

Under the terms of the deal, Novartis will be responsible for Phase 1 trials, regulatory submissions, and “affordable” distribution of the drug. DNDi will lead Phase 2 and 3 development, with the…

Japan’s Global Health Innovative Technology Fund awarded $5.9 million in funding this week to eight projects seeking to develop diagnostics, drugs and vaccines for Chagas disease, leishmaniasis, malaria and tuberculosis (TB).

Industry recipients included Takeda, with three malaria awards and one TB drug award, and Mitsubishi Tanabe Pharma Company, with one Chagas and leishmaniasis drug award.

The Ohio State University (OSU) College of Medicine announced last week that Britain’s Wellcome Trust has given it $650,000 to test a visceral leishmaniasis (VL) vaccine in dogs to reduce their risk as carriers.

In March, Japan’s Global Health Innovative Technology (GHIT) Fund also awarded the college $3.6 million to support manufacturing of clinical-grade materials in preparation for human VL vaccine trials.

Japan’s Global Health Innovative Technology Fund (GHIT) announced last week that it has appointed BMS executive Catherine Ohura as its new CEO and executive director, effective April 1. Ohura replaces founding CEO BT Slingsby, who announced last September that he would be stepping down at the end of Japan’s 2018 fiscal year (March 2019).

Last week, GHIT also announced $25.8 million in new product development funding for malaria, TB, dengue, leishmaniasis and schistosomiasis. The…

The Drugs for Neglected Diseases initiative (DNDi) announced this week that Britain’s Wellcome has given it nearly $13 million to develop new, all-oral drugs to treat leishmaniasis with pharmaceutical companies Celgene, GSK, Pfizer and Takeda, along with a consortium of other R&D partners.

According to a company press release, the three-year program will assess 10 drug candidates and hopes to advance two as a combination therapy through Phase 2.

Japan’s Global Health Innovative Technology Fund (GHIT) announced last week $4.6 million in new product development funding for malaria, tuberculosis, dengue and leishmaniasis.

The majority of the funds will be invested in preclinical development of VLP Therapeutics’ flavivirus dengue vaccine.